Plain English Summary
Background and study aims
Currently the antibiotic ceftriaxone is used to treat gonorrhoea but there is increasing evidence that this antibiotic is becoming less effective over time and will stop curing patients with gonorrhoea within the next few years. Many currently available antibiotics do not work against gonorrhoea and there is an urgent need to find an alternative treatment which is effective and safe. Gentamicin which is an existing antibiotic, might be effective against gonorrhoea. Testing in the laboratory suggests that gentamicin could be used to treat gonorrhoea, and it has been used as a treatment in some developing countries with success. A review looking for previously published studies which assessed gentamicin found that the existing trials are of low quality and that there are no recent clinical trials. Therefore a randomised study to compare the efficacy of ceftriaxone and gentamicin has been designed. This will assess whether gentamicin is a safe and effective treatment for gonorrhoea.
Who can participate?
Patients diagnosed with gonorrhoea infection will be asked to join the study
What does the study involve?
and be randomised to receive either gentamicin or ceftriaxone. Both are given by injection. All patients will also receive azithromycin which is currently given in combination with ceftriaxone in the treatment of gonorrhoea. Patients will be asked to come back to clinic 2 weeks after their treatment to be tested to see if their gonorrhoea has cleared. The safety of both antibiotics will also be assessed.
What are the possible benefits and risks of participating?
There are no direct benefits for the participant of taking part in the study. However, the information we get from this study will help us to see if gentamicin is as good as ceftriaxone. This could benefit patients with gonorrhoea in the future. Although previous studies suggest that it is effective, there is a risk that gentamicin may not work as well as ceftriaxone and that participants may have to have further treatment. There is also a risk of side effects from both antibiotics, although we think this risk is low as they are only given once. Ceftriaxone can cause diarrhoea, anaemia, abnormalities in white blood cells and problems with kidney and liver function. Gentamicin can cause problems with hearing, balance and kidney function.
Where is the study run from?
Notitngham Clinical Trials Unit, UK
When is the study starting and how long is it expected to run for?
October 2014 to December 2016
Who is funding the study?
National Institute for Health Research (NIHR) UK
Who is the main contact?
Miss Clare Brittain
Miss Clare Brittain
Queens Medical Centre
17433; HTA 12/127/10
A randomised controlled trial to compare the clinical effectiveness and safety of gentamicin and ceftriaxone in the treatment of gonorrhoea
The study is to trying to find out whether gentamicin is an acceptable alternative to ceftriaxone, in the treatment of gonorrhoea. This will be done by determining whether the clearance rate of gonorrheoa in participants receiving gentamicin is no worse than the rate in participants receiving ceftriaxone. In parallel, the safety of both treatments will be assessed.
More details can be found at: http://www.nets.nihr.ac.uk/projects/hta/1212710
South Central - Oxford C REC; ref: 14/SC/1030
Randomised; Interventional; Design type: Not specified
Primary study design
Secondary study design
Randomised controlled trial
Patient information sheet
Not available in web format, please use the contact details to request a patient information sheet
Topic: Infectious diseases and microbiology; Subtopic: Infection (all Subtopics); Disease: Infectious diseases and microbiology
Gentamicin (240 mg), Gentamicin (240 mg) vs Ceftriaxone (500 mg) for the treatment of gonorrhoea. Participants will be randomised to receive a single intramuscular injection of gentamicin (240 mg) or ceftriaxone (500 mg). All participants will also receive a single oral dose of azithromycin (1 g) as standard care.
Gentamicin, ceftriaxone, azithromycin
Primary outcome measure
Clearance of N. gonorrhoeae at all the infected sites confirmed by a negative NAAT (Aptima Combo), two weeks post treatment (as recommended by the British Association for Sexual Health and HIV).
Secondary outcome measures
1. Clinical resolution of symptoms
2. Frequency of nausea/vomiting, hearing loss, dizziness and rash
3. Frequency of other adverse events
4. Tolerability of therapy
5. Relationship between clinical effectiveness and MIC to inhibit N. gonorrhoeae growth
6. Cost effectiveness
Overall trial start date
Overall trial end date
Reason abandoned (if study stopped)
Participant inclusion criteria
1. Aged 16-70 years
2. Diagnosis of uncomplicated untreated genital, pharyngeal or rectal gonorrhoea based on a positive gram stained smear on microscopy, or positive NAAT
3. Written informed consent provided
Target number of participants
Planned Sample Size: 720; UK Sample Size: 720
Participant exclusion criteria
1. Known concurrent bacterial sexually transmitted infection (apart from chlamydia)
2. Known contraindications or allergy to gentamicin, ceftriaxone, azithromycin or lidocaine
3. Pregnant or breastfeeding
4. Current clinical diagnosis of complicated gonorrhoea infections eg pelvic inflammatory disease, epididymoorchitis
5. Weight less than 40kg at the time of randomisation
6. Currently receiving or have received ceftriaxone or gentamicin within the preceding 28 days
7. Previous participation in this study
Recruitment start date
Recruitment end date
Countries of recruitment
Trial participating centre
Queens Medical Centre
Health Technology Assessment Programme
NIHR Health Technology Assessment Programme, HTA
Funding Body Type
Funding Body Subtype
Results and Publications
Publication and dissemination plan
Not provided at time of registration
IPD sharing statement
The datasets analysed during the current study will be available upon request from the NCTU (firstname.lastname@example.org), a minimum of 6 months after publication of the main results paper. Access to the data will be subject to review of a data sharing and use request by a committee including the CI and sponsor, and will only be granted upon receipt of a data sharing and use agreement. Any data shared will be pseudo anonymised which may impact on the reproducibility of published analyses.
Intention to publish date
Participant level data
Available on request
Basic results (scientific)
2016 protocol in: https://www.ncbi.nlm.nih.gov/pubmed/27881151